A phase III trial of adjuvant Prolia (denosumab) therapy in postmenopausal women with early hormone receptor positive breast cancer receiving aromatase inhibitor therapy met its primary endpoint of time from randomization to first clinical fracture (HR=0.5, 95 percent CI 0.39-0.65, p<0.0001).
The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.
